Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Mylan
30 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
Donation
Mylan and Sesame Workshop Partner to Provide Socio-Emotional Support Resources to Families Impacted by COVID-19
PR-M08-20-NI-22
COVID-19 Treatment
Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19
PR-M05-20-NI-018
Leadership
Mylan Board Appoints Robert J. Coury As Executive Chairman
PR-M04-20-NI-026
M&A
Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn
PR-M03-20-NI-041
BLA
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
PR-M03-20-NI-014
Legal Settlement
Mylan Finalizes Previously Disclosed Settlement with U.S. Securities and Exchange Commission
PR-M09-19-NI-060
Legal
Celgene to pay Mylan $62 Million to Resolve Cancer Drug Antitrust Case
PR-M08-19-NI-007
M&A
Mylan and Upjohn, a Division Of Pfizer, to Combine
PR-M07-19-NI-079
Recall
Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter
PR-M03-19-NI-050
Opioids
Generic Suboxone Sublingual Film Launched
PAO-M03-19-NI-004
FDA Approval
Mylan Announces FDA Approval of Wixela™ Inhub™, First Generic of ADVAIR DISKUS®
PR-M02-19-NI-005
Launch
Launch of Generic Lialda® Delayed-Release Tablets Expands Mylan's Gastroenterology Product Offering
PR-M01-19-NI-001
Gastroenterology
Mylan Expands Gastroenterology Portfolio with Launch of Generic for Prevacid® SoluTab Delayed-Release Orally Disintegrating Tablets
PR-M12-18-NI-022
FDA Inspection
Mylan Statement in Response to FDA Warning Letter Relating to Morgantown Plant
PR-M11-18-NI-093
Biosimilars
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
PR-M10-18-NI-071
Clinical Data
Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
PR-M10-18-NI-038
Generics
Mylan Launches Authorized Generic of Ampyra® Tablets
PR-M09-18-NI-089
Biosimilar
Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
PR-M09-18-NI-087
Generics
Mylan Launches First Generic for Adcirca® Tablets
PR-M09-18-NI-021
Biosimilar
Mylan and Fujifilm Kyowa Kirin Biologics Announce Positive CHMP Opinion for Hulio™, Biosimilar Adalimumab
PR-M08-18-NI-001
Drug Development
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon® Patch
PR-M07-18-NI-028
HIV
Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment in the U.S.
PR-M03-18-NI-111
Drug Development
Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.
PR-M03-18-NI-023
Biosimilar
Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics
PR-M03-18-NI-017
1
2
»